Want to continue viewing company data?

Sign up for exclusive competitive intelligence.
Company Data Subscription $329 per month (billed Annually)
Signup to View Free Sample

Evotec SE (Evotec) is a drug discovery alliance and development partnership company. It discovers and develops small molecule drugs spanning various conditions areas such as oncology, neurological and nephrological conditions, cardiovascular, inflammation, pain, metabolic and respiratory diseases. Evotec provides drug discovery services such as target identification and validation, hit identification, sample management, in vitro pharmacology services, integrated CMC, and proteomics services. The company has long-term discovery alliances with several leading pharmaceutical companies and development partnerships for product candidates in clinical and pre-clinical development stages. The company has operating facilities in Abingdon and Alderley Park, the UK; Gottingen and Munich, Germany; Orth an der Donau, Austria; Branford, Princeton and Watertown, the US; Verona, Italy; and Toulouse and Lyon, France. Evotec is headquartered in Hamburg, Germany.

Headquarters Germany

Address Essener Bogen 7, Hamburg, 22419


Telephone 49 40 560810

No of Employees 4,354

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange EVT (ETR)

Revenue (2021) $730.8M 12.2% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX -83.6% (2021 vs 2020)

Market Cap* $4.4B

Net Profit Margin (2020) XXX -85.4% (2021 vs 2020)

* As of and is in US$

Explore premium data & analytics

200+

Pipeline Drugs

Identify which of Evotec SE’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

70+

Clinical Trials

Determine Evotec SE go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

50+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Evotec SE’s relevant decision makers and contact details.

30+

Catalyst Calendar

Proactively evaluate Evotec SE’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

20+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

10+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Services Brands
Technologies: Drug Discovery J. DISCOVERY
Induced Pluripotent Stem Cells (IPSC) Drug Discovery Platform Target Identification and Validation J. MD
J. DESIGN Hit Identification JP3
XXX XXX
XXX XXX
XXX XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Contracts/Agreements In June, the company entered into a drug discovery collaboration with Janssen Pharmaceutica NV to jointly conduct screens on the identified targets.
2022 Contracts/Agreements In May, the company entered into an agreement to acquire 100% stake in Rigenerand, an Italy-based cell technology firm for US$24.7 million.
2022 Contracts/Agreements In May, the company and Almirall entered into a multi-target alliance in Medical Dermatology.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Evotec SE Merck & Co Inc AstraZeneca Plc GW Pharmaceuticals Plc Cobra Biologics Ltd
Headquarters Germany United States of America United Kingdom United Kingdom United Kingdom
City Hamburg Whitehouse Station Cambridge Cambridge Keele
State/Province - New Jersey Cambridgeshire Cambridgeshire Staffordshire
No. of Employees 4,354 68,000 83,100 - 140
Entity Type Public Public Public Private Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Werner Lanthaler, Ph.D. Chief Executive Officer Senior Management 2009 54
Enno Spillner Chief Financial Officer Senior Management 2016 52
Craig Johnstone, Ph.D. Chief Operating Officer Senior Management 2019 52
Cord Dohrmann, Ph.D. Chief Scientific Officer Senior Management 2010 58
Dr. Iris Low-Friedrich Vice Chairman Executive Board 2019 62
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer